ConductScience.org, home

Paper36712949

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.

Soriano V and 4 others. Drug Des Devel Ther, 2023. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy. Papers, record 36712949. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36712949

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
2.39
iCite
Revised in PubMed
2026-01-27
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Soriano VVicente
2Moreno-Torres VVictor
3Treviño AAna
4Corral OOctavio
5de Mendoza CCarmenhttps://orcid.org/0000-0001-5224-7492

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis B Surface AntigensMajor topic
Hepatitis Delta VirusMajor topic
Animals
Humans
Drug Discovery
Hepatitis B virus
RNA
Lipopeptides

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03852433Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Background

Source ClinicalTrials.gov

Download CSV of trials

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127132172First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.J Hepatol2016https://conductscience.org/library/papers/27132172PubMed
229217749Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.Gut2019https://conductscience.org/library/papers/29217749PubMed
335973578Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.J Hepatol2022https://conductscience.org/library/papers/35973578PubMed
433999515Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.Liver Int2021https://conductscience.org/library/papers/33999515PubMed
523150796Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.Elife2012https://conductscience.org/library/papers/23150796PubMed
635656722T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide.Liver Int2022https://conductscience.org/library/papers/35656722PubMed
734699951Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.J Hepatol2022https://conductscience.org/library/papers/34699951PubMed
835631038Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.Pathogens2022https://conductscience.org/library/papers/35631038PubMed
935942695Bulevirtide for patients with compensated chronic hepatitis delta: A review.Liver Int2023https://conductscience.org/library/papers/35942695PubMed
1031872446Spontaneous Clearance of Chronic Delta Hepatitis.Hepatology2020https://conductscience.org/library/papers/31872446PubMed
1134482769Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.Expert Opin Investig Drugs2022https://conductscience.org/library/papers/34482769PubMed
1232926353Bulevirtide: First Approval.Drugs2020https://conductscience.org/library/papers/32926353PubMed
1333807170In Vivo Models of HDV Infection: Is Humanizing NTCP Enough?Viruses2021https://conductscience.org/library/papers/33807170PubMed
1432398799Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.Sci Rep2020https://conductscience.org/library/papers/32398799PubMed
1535934855Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' reply.Aliment Pharmacol Ther2022https://conductscience.org/library/papers/35934855PubMed
1633845061Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.J Hepatol2021https://conductscience.org/library/papers/33845061PubMed
1736004554Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre.Liver Int2022https://conductscience.org/library/papers/36004554PubMed
1831292511Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus.Sci Rep2019https://conductscience.org/library/papers/31292511PubMed
1935514008Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.Aliment Pharmacol Ther2022https://conductscience.org/library/papers/35514008PubMed
2031541699Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection.Int J Antimicrob Agents2019https://conductscience.org/library/papers/31541699PubMed

See all 51 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42713260New Developments in the Treatment of Hepatitis B Virus Infection.Gastroenterol Hepatol (N Y)2026https://conductscience.org/library/papers/42713260PubMed
42630452Serum PreS1 antigen combined with vascular endothelial growth factor can identify low-level hepatitis B virus DNA replication in patients with hepatitis B e antigen-negative chronic infection.Am J Transl Res2026https://conductscience.org/library/papers/42630452PubMed
42486799Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.Hepatol Commun2026https://conductscience.org/library/papers/42486799PubMed
42057812Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis.Int J Hepatol2026https://conductscience.org/library/papers/42057812PubMed
41642349Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches.Curr Microbiol2026https://conductscience.org/library/papers/41642349PubMed
40718095Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.Curr Res Pharmacol Drug Discov2025https://conductscience.org/library/papers/40718095PubMed
40620504Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver Res2025https://conductscience.org/library/papers/40620504PubMed
40606936Hope on the horizon: Emerging therapies for hepatitis D.World J Hepatol2025https://conductscience.org/library/papers/40606936PubMed
40038382Current prevalence of hepatitis delta diagnosis in Valencia, Spain.Sci Rep2025https://conductscience.org/library/papers/40038382PubMed
40006617Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions.Pharmaceutics2025https://conductscience.org/library/papers/40006617PubMed
39100818Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.JHEP Rep2024https://conductscience.org/library/papers/39100818PubMed
39081834Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease.Can J Gastroenterol Hepatol2024https://conductscience.org/library/papers/39081834PubMed
38977324Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.Pharmacol Rev2024https://conductscience.org/library/papers/38977324PubMed
38668246Prospects for Controlling Hepatitis B Globally.Pathogens2024https://conductscience.org/library/papers/38668246PubMed
38617106The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies.J Clin Exp Hepatol2024https://conductscience.org/library/papers/38617106PubMed
38353882Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.Drug Saf2024https://conductscience.org/library/papers/38353882PubMed
37488783Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States.J Viral Hepat2023https://conductscience.org/library/papers/37488783PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CXCL103627PubTator's text mininghttps://conductscience.org/library/genes/3627NCBI Gene
ISG159636PubTator's text mininghttps://conductscience.org/library/genes/9636NCBI Gene
SLC10A16554PubTator's text mininghttps://conductscience.org/library/genes/6554NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36712949

GET https://conductscience.org/api/papers/v1/36712949/references?page=2